News & Updates

For people with long-term stable multiple sclerosis (MS) who use disease-modifying therapy (DMT) in the first-line setting, discontinuation spells an increased hazard of inflammatory disease activity recurrence, as shown in a study.

In the treatment of women with early pregnancy loss, adding mifepristone to misoprostol helps reduce the incidence of treatment failure as compared with misoprostol alone, according to a retrospective study.

Healthcare workers who developed depression in the course of frontline work during the COVID-19 pandemic experienced substantial reductions in symptoms following psilocybin treatment, as shown in a small randomized clinical trial.

In the treatment of hospitalized adults with COVID-19 and hypoxemia, the use of the spleen tyrosine kinase inhibitor fostamatinib does not appear to have any positive effect on the number of oxygen-free days as compared with placebo, according to the results of a phase III trial.

In the treatment of patients with atrial fibrillation (AF), direct oral anticoagulants (DOACs) do not contribute to an increased risk of intracranial haemorrhage compared with antiplatelet therapy, according to the results of a systematic review and meta-analysis.

Dual inhibition of EZH1/2 with valemetostat appears to induce responses in patients with relapsed or refractory peripheral T-cell lymphoma while having a manageable safety profile, according to the results of a single-arm phase II trial.

Among patients with primary biliary cholangitis (PBC), treatment with elafibranor improved predicted transplant-free survival rates based on improvements in GLOBE and UK-PBC scores, according to the phase III ELATIVE trial presented at The Liver Meeting 2024.

In patients with type 2 diabetes (T2D), treatment with empagliflozin has a null effect on the risk of nonproliferative diabetic retinopathy (NPDR) compared with a DPP-4 inhibitor but may confer protection against DR progression, according to a study.